Since many phytocannabinoids, as well as mixed cannabinoid agonists, also show an affinity for the CB1R but do not induce respiratory depression (Wiese et al., 2020), understanding how CB1R activation drives respiratory depression is vital to ensuring safe consumption of these opioid adjuncts. This evidence concerns the gene CNR1 and Respiratory insufficiency due to muscle weakness.